Clear Impact logo

Vermont Medicaid

SSD: Diabetes Scrng for People w/ Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications - Age 18-64 (ACS-21)

Current Value

67.7%

2021

Definition

Line Bar

Notes on Methodology

  • The target trendline in the graph above represents an accepted national benchmark percentile for Medicaid programs across the country. The value graphed historically was the national 50th percentile for comparison purposes. In 2020 (for measurement year 2019) we modified the value shown to demonstrate a target based on our actual performance.  For this measure, the target is the 25th national percentile.
  • The annual reported rate captures activity during the previous calendar year. 
  • This is a Healthcare Effectiveness & Data Information Set (HEDIS) administrative measure.
  • DVHA’s rates only include Medicaid Primary beneficiaries in HEDIS administrative measures. 

Story Behind the Curve

This measure assesses the percentage of members 18-64 years of age with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening during the measurement year.

People with schizophrenia are at greater risk of metabolic syndrome due to their serious metal illness.  Diabetes screening is important for anyone with schizophrenia or bipolar disorder, and the added risk associated with antipsychotic medications contributes to the need to screen people with schizophrenia for diabetes.  Diabetes screening for individuals with schizophrenia or bipolar disorder who are prescribed an antipsychotic medication may lead to earlier identifcation and treatment of diabetes.

Last updated:  August 2021

Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.

Scorecard Container Measure Action Actual Value Target Value Tag S A m/d/yy m/d/yyyy